X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs STERLING BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA STERLING BIOTECH GSK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 60.9 -0.4 - View Chart
P/BV x 11.4 0.0 79,924.0% View Chart
Dividend Yield % 2.5 0.0 -  

Financials

 GSK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
STERLING BIOTECH
Dec-13
GSK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,76011 26,285.7%   
Low Rs2,0403 60,000.0%   
Sales per share (Unadj.) Rs339.026.8 1,264.7%  
Earnings per share (Unadj.) Rs41.4-15.0 -276.9%  
Cash flow per share (Unadj.) Rs45.9-5.5 -840.3%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.954.9 442.6%  
Shares outstanding (eoy) m84.70267.87 31.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.10.3 2,730.6%   
Avg P/E ratio x57.9-0.5 -12,470.7%  
P/CF ratio (eoy) x52.3-1.3 -4,109.5%  
Price / Book Value ratio x9.90.1 7,802.5%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,2801,862 10,919.1%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m5,234547 957.2%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m28,7157,181 399.9%  
Other income Rs m54543 1,280.4%   
Total revenues Rs m29,2607,223 405.1%   
Gross profit Rs m5,059947 534.2%  
Depreciation Rs m3802,543 14.9%   
Interest Rs m24,377 0.0%   
Profit before tax Rs m5,222-5,931 -88.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892-1,924 -98.3%   
Profit after tax Rs m3,508-4,007 -87.6%  
Gross profit margin %17.613.2 133.6%  
Effective tax rate %36.232.4 111.7%   
Net profit margin %12.2-55.8 -21.9%  
BALANCE SHEET DATA
Current assets Rs m21,81514,335 152.2%   
Current liabilities Rs m15,99949,809 32.1%   
Net working cap to sales %20.3-494.0 -4.1%  
Current ratio x1.40.3 473.8%  
Inventory Days Days64403 15.8%  
Debtors Days Days19171 11.0%  
Net fixed assets Rs m12,47555,432 22.5%   
Share capital Rs m847268 316.2%   
"Free" reserves Rs m19,72613,935 141.6%   
Net worth Rs m20,57314,701 139.9%   
Long term debt Rs m69,478 0.1%   
Total assets Rs m39,47573,988 53.4%  
Interest coverage x2,612.0-0.4 -735,855.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.70.1 749.5%   
Return on assets %8.90.5 1,775.2%  
Return on equity %17.1-27.3 -62.6%  
Return on capital %26.2-6.4 -408.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m5641,860 30.3%   
Fx outflow Rs m7,42925 29,847.3%   
Net fx Rs m-6,8651,835 -374.1%   
CASH FLOW
From Operations Rs m4,7281,719 275.1%  
From Investments Rs m-1,042-3,148 33.1%  
From Financial Activity Rs m-3,0661,426 -215.0%  
Net Cashflow Rs m620-3 -18,226.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.0 -  
FIIs % 23.8 9.9 240.4%  
ADR/GDR % 0.0 16.9 -  
Free float % 15.4 39.3 39.2%  
Shareholders   102,036 21,482 475.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SHASUN PHARMA  WYETH LTD  ASTRAZENECA PHARMA  ALEMBIC LTD  CIPLA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - BIOCON LTD COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS